These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28631864)

  • 1. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Chotibut T; Meadows S; Kasanga EA; McInnis T; Cantu MA; Bishop C; Salvatore MF
    Mov Disord; 2017 Nov; 32(11):1547-1556. PubMed ID: 28631864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
    Kelsey JE; Neville C
    Psychopharmacology (Berl); 2014 Jun; 231(12):2405-15. PubMed ID: 24402134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
    J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Schuster S; Doudnikoff E; Rylander D; Berthet A; Aubert I; Ittrich C; Bloch B; Cenci MA; Surmeier DJ; Hengerer B; Bezard E
    Biol Psychiatry; 2009 Mar; 65(6):518-26. PubMed ID: 18947822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
    Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
    Yamamoto N; Soghomonian JJ
    Neuroscience; 2009 Nov; 163(4):1171-80. PubMed ID: 19660528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
    Huang YT; Chen YW; Lin TY; Chen JC
    Neurobiol Dis; 2024 Apr; 193():106452. PubMed ID: 38401650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Boi L; Pisanu A; Greig NH; Scerba MT; Tweedie D; Mulas G; Fenu S; Carboni E; Spiga S; Carta AR
    Mov Disord; 2019 Dec; 34(12):1818-1830. PubMed ID: 31335998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.
    Chotibut T; Davis RW; Arnold JC; Frenchek Z; Gurwara S; Bondada V; Geddes JW; Salvatore MF
    Mol Neurobiol; 2014 Jun; 49(3):1282-92. PubMed ID: 24297323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.